00:00It is a very important day because fenfluramine is finally available also in Italy for the
00:09Lennon-Gastaut syndrome.
00:10It is a very important step because we are talking about a rare pathology in which the
00:15therapeutic outlook is not yet sufficient to meet the needs of these patients, because
00:23they typically speak with resistance.
00:25Fenfluramine is able to reduce epileptic crises in a decisive and long-term way and therefore
00:31to contribute in a clear way to the quality of life of the patient and his family, but
00:36also to the whole picture of the comorbidities that are accompanied in this pathology.
00:44As UCB we do it not only with attention to the molecule and research, but also by supporting
00:52all those initiatives that are around in the life of these patients, therefore favoring
00:58multidisciplinarity, favoring what is the transition from the pediatric age to the
01:04adult age and also an attention to all those that are the social assistance services
01:09that are fundamental in the life of the families of these patients.
Comments